The analysis used baseline data from the E-CHAMP prospective registry, which consecutively recruited community-dwelling residents from eight communities in Chengdu’s Xindu District between 2024 and 2026. Eligible participants were at least 45 years old, had no prior or current diagnosis of diabetes and had complete clinical, laboratory, anthropometric and imaging information. People with symptomatic cerebrovascular disease, including ischemic stroke or transient ischemic attack attributed to cerebrovascular stenosis, were excluded, as were individuals with coronary artery disease, severe liver or kidney dysfunction, psychiatric disorders or missing imaging and measurements required for the analysis. Of 800 enrolled adults, 604 were included; the mean age was 64 years, with a standard deviation of 11, and 220 participants, or 36.4%, were male.

Estimated glucose disposal rate, abbreviated eGDR, is a non-invasive composite surrogate for insulin resistance. The score combines hypertension status, waist-to-hip ratio and glycated hemoglobin, or HbA1c, to summarize metabolic conditions associated with the body’s ability to handle glucose. Higher eGDR values indicate better insulin sensitivity, whereas lower values indicate greater insulin resistance. The measure is especially relevant in people whose fasting glucose and HbA1c have not reached diabetic ranges but who may nevertheless harbor metabolic abnormalities associated with vascular injury. The investigators did not directly measure insulin resistance with a hyperinsulinemic-euglycemic clamp, so their results concern the composite metabolic status represented by eGDR rather than a directly quantified physiological state.

Cerebrovascular atherosclerosis was evaluated with carotid duplex ultrasonography, head-and-neck magnetic resonance angiography or head-and-neck computed tomography angiography, according to the imaging protocol and clinical practice. Two experienced neurologists independently reviewed the studies without access to participants’ clinical and laboratory data and resolved differences by consensus. The intracranial bed included the intracranial internal carotid, middle cerebral, anterior cerebral, posterior cerebral, vertebral and basilar arteries. The extracranial bed included the common carotid, extracranial internal carotid, vertebral and subclavian arteries. Involvement was defined as plaque and/or stenosis in a bed. Participants were then placed in three categories: no atherosclerosis, single vascular bed involvement, or involvement in both beds.

Of the 604 analyzed adults, 383, or 63.4%, had no cerebrovascular atherosclerosis, 164, or 27.2%, had disease in one vascular bed, and 57, or 9.4%, had disease in both beds. Participants with more extensive involvement were older and more likely to have hypertension, while their baseline eGDR values were lower. Across eGDR quartiles, the clearest gradient appeared in the prevalence of vascular involvement. Single-bed disease occurred in 33.1% of those in the lowest eGDR quartile, compared with 19.2% in the highest quartile. Dual-bed involvement fell from 13.2% in the lowest quartile to 2.0% in the highest. These are cross-sectional prevalence differences, not evidence that a change in eGDR would reduce existing disease.

Ordinal logistic regression was used to test whether higher eGDR corresponded to a lower probability of occupying a higher burden category. The unadjusted odds ratio was 0.67 per one-standard-deviation increase in eGDR, with a 95% confidence interval of 0.56 to 0.79. Adjustment for age and sex produced a similar estimate of 0.73, with a 95% confidence interval of 0.61 to 0.87. In the fully adjusted model, which additionally accounted for smoking, alcohol consumption, alanine aminotransferase, aspartate aminotransferase, uric acid, triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol, the odds ratio was 0.74, with a 95% confidence interval of 0.62 to 0.89 and p=0.001. When eGDR was divided into quartiles, participants in the highest quartile had lower odds of greater burden than those in the lowest quartile: the adjusted odds ratio was 0.42, with a 95% confidence interval of 0.24 to 0.72 and p=0.001. The trend across quartiles was significant at p=0.002.

Restricted cubic spline analysis indicated that the dose–response relationship was consistent with a linear pattern. The overall association between eGDR and cerebrovascular burden was significant at p=0.002, while the test for nonlinearity was not significant at p=0.322. The analysis therefore did not detect a threshold, plateau or acceleration in the relationship within the observed distribution. A separate binary analysis that combined single- and dual-bed involvement into a single category of any cerebrovascular atherosclerosis also found an inverse association: the fully adjusted odds ratio per one-standard-deviation increase in eGDR was 0.72, with a 95% confidence interval of 0.60 to 0.87 and p<0.001. These results support a graded cross-sectional association rather than a pattern appearing only among people with the most advanced imaging abnormalities.

Subgroup analyses revealed that the relationship was generally similar across age, sex, body mass index, smoking status and LDL cholesterol category, but hypertension status modified the association. Among participants without hypertension, each one-standard-deviation increase in eGDR was associated with lower odds of greater atherosclerotic burden, with an odds ratio of 0.44, a 95% confidence interval of 0.23 to 0.85 and p=0.014. No significant association was detected among participants with hypertension: the odds ratio was 1.04, with a 95% confidence interval of 0.62 to 1.74 and p=0.892. The interaction was significant at p=0.003. Because hypertension is itself a component of the standard eGDR equation, the researchers repeated the analysis with a modified score that omitted hypertension. The interaction remained significant at p=0.002, suggesting it could not be explained solely by mathematical coupling, although the finding does not establish a biological interaction.

Component analyses further showed that hypertension was associated with higher cerebrovascular burden, with an odds ratio of 1.80 in a hypertension-only model and 1.79 in a model including hypertension, waist-to-hip ratio and HbA1c; both had p=0.001. Waist-to-hip ratio and HbA1c were not significantly associated with burden after mutual adjustment. The findings therefore cannot separate insulin resistance itself from the hypertension and adiposity information embedded in eGDR. They also do not show that eGDR provides useful predictive information beyond those components. Mechanistic explanations involving endothelial dysfunction, inflammation, oxidative stress, disturbed blood flow and vascular remodeling remain plausible, but the cross-sectional data cannot test them.

Several limitations constrain the conclusions. The single-region sample consisted mainly of middle-aged and older adults in Southwest China, and the findings may not generalize to populations with different body composition, metabolic profiles, vascular risks or healthcare systems. Roughly one-quarter of the initially eligible registry participants were excluded because imaging or anthropometric data were missing; although included and excluded groups had broadly similar baseline characteristics, selection bias cannot be ruled out. The use of three imaging modalities may also have introduced variation in lesion detection, despite predefined criteria and blinded review by two neurologists. Residual confounding, measurement error and possible misclassification remain possible. Most importantly, the cross-sectional design cannot determine temporal order or causation, and eGDR was not validated against a direct insulin-resistance test in this cohort. Prospective studies in more diverse populations, with repeated metabolic and vascular measurements, are needed to determine whether the association persists over time and whether eGDR offers value beyond its individual components.

Subject of Research: Association between estimated glucose disposal rate and subclinical cerebrovascular atherosclerotic burden in adults without diabetes

Article Title: Association between estimated glucose disposal rate and subclinical cerebrovascular atherosclerotic burden in non-diabetic middle-aged and older adults

Article References: Guo, L., Zhao, Y., Qu, M., Li, M., Zhu, J., Zheng, S., & Zhang, J. (2026). Association between estimated glucose disposal rate and subclinical cerebrovascular atherosclerotic burden in non-diabetic middle-aged and older adults. Frontiers in Neurology, 17, Article 1946802. https://doi.org/10.3389/fneur.2026.1946802

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1946802

Keywords: eGDR, insulin resistance, cerebrovascular atherosclerosis, intracranial stenosis, carotid plaque, vascular imaging, cross-sectional study, non-diabetic adults, hypertension, metabolic health, Association, between

To understand why inflammation matters so much in this context, it helps to revisit what adipose tissue actually does. Far from being a passive energy depot, fat tissue is an active endocrine organ. In obesity, enlarged and stressed adipocytes begin releasing pro-inflammatory signaling molecules, including tumor necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1, while macrophages infiltrate the tissue and amplify the inflammatory cascade. This chronic, systemic low-grade inflammation is now recognized as a central driver of insulin resistance, atherosclerosis, and cardiometabolic risk. Because of this, researchers have long suspected that effective weight-loss therapies might deliver a double payoff: direct metabolic improvement and a measurable cooling of the inflammatory state. The new meta-analysis puts that hypothesis to a rigorous test for one of the most consequential weight-loss drugs on the market.

Semaglutide works by mimicking glucagon-like peptide-1, a gut-derived incretin hormone that the body releases after meals. By binding to and activating the GLP-1 receptor, the drug slows gastric emptying, enhances the sensation of satiety in the brain, and reduces appetite, all of which lead to a sustained caloric deficit. Approved initially for type 2 diabetes and later for chronic weight management, semaglutide has demonstrated some of the largest pharmacological weight reductions ever recorded in obesity trials. But GLP-1 receptors are not confined to the pancreas, gut, and hypothalamus; they are also expressed on immune cells, including macrophages, which has led to speculation that the drug might dampen inflammation both indirectly, through weight loss itself, and directly, through receptor-mediated effects on immune signaling pathways.

Disentangling those two mechanisms is precisely what makes a systematic review and meta-analysis valuable. Individual trials of semaglutide in people without diabetes have typically been powered to detect weight change, not shifts in circulating inflammatory markers, so single studies often report inconclusive or heterogeneous results on inflammation. By aggregating data across trials, the authors of the new analysis could extract a clearer signal, quantifying the average effect of subcutaneous semaglutide on body weight and on key inflammatory biomarkers—most notably high-sensitivity C-reactive protein, the liver-produced sentinel molecule that rises in response to systemic inflammation and is one of the most robust predictors of cardiovascular events in observational studies.

The population under scrutiny is also worth emphasizing. Most of the early evidence for semaglutide’s metabolic benefits came from trials that enrolled people with type 2 diabetes, leaving open the question of whether the drug’s metabolic and anti-inflammatory effects apply to the much larger population of adults with overweight or obesity who have never developed diabetes. The trials included in this review focused specifically on that non-diabetic group, which matters because their baseline metabolism differs in important ways: insulin secretion is generally more preserved, beta-cell function is more intact, and the drivers of their inflammation are more closely tied to adiposity itself than to diabetic dysglycemia. Any anti-inflammatory benefit seen in this population is therefore more likely attributable to the drug’s effects on fat mass and appetite regulation rather than to improved glucose control.

The findings, synthesized across the pooled trials, support the picture that has emerged from the landmark semaglutide weight-management program: substantial and clinically meaningful weight reduction in adults treated with the medication compared with placebo. Equally significant, the analysis evaluated changes in inflammatory markers alongside the weight outcomes, addressing whether the drug’s metabolic benefits are accompanied by reductions in the molecular signatures of chronic inflammation. This paired assessment is important for clinicians, because cardiovascular guidelines increasingly treat inflammation as a therapeutic target in its own right. If a weight-loss drug reliably lowers both body weight and C-reactive protein, its case as a preventive intervention becomes considerably stronger than if it merely changes a number on the scale.

For readers following the cultural moment around GLP-1 drugs, the scientific stakes of analyses like this one are hard to overstate. Semaglutide and related incretin therapies have moved from diabetes clinics into mainstream medicine at extraordinary speed, and demand has at times outstripped supply. Health systems are now grappling with questions about which patients should receive these medications, how long treatment should continue, and what the long-term benefits and risks are. Evidence connecting semaglutide to reduced inflammation in people without diabetes feeds directly into those deliberations, because it suggests the drug may address a broader swath of obesity-related pathology than weight loss alone would predict, potentially altering trajectories of cardiovascular and inflammatory disease in a patient population that has historically had limited pharmacological options.

At the same time, the authors and observers of this evidence base caution that meta-analyses inherit the limitations of the trials they aggregate. The number of trials reporting inflammatory markers in non-diabetic populations remains relatively modest, follow-up durations in weight-management trials are typically measured in months rather than years, and the standardization of inflammatory marker assays can vary between studies. Weight loss itself, achieved by any means—diet, exercise, or surgery—is known to reduce C-reactive protein and other inflammatory markers, so a central interpretive question is how much of the anti-inflammatory effect reflects the magnitude of weight reduction versus a direct pharmacological action on immune cells. The meta-analytic framework allows researchers to begin teasing these contributions apart, but definitive answers will require dedicated trials with inflammation as a primary endpoint and longer observation windows.

Those caveats notwithstanding, the broader trajectory of the evidence is coherent. Across diabetes and non-diabetes populations alike, GLP-1 receptor agonism is emerging as a lever that moves multiple cardiometabolic dials simultaneously: appetite, body weight, glycemia where relevant, and systemic inflammation. Large cardiovascular outcomes trials of semaglutide in high-risk populations have already demonstrated reductions in major adverse cardiovascular events, and mechanistic work suggests that attenuation of vascular and adipose inflammation may be part of the explanation. The new review in the International Journal of Obesity extends this logic to adults with overweight or obesity without diabetes, the very population in which preventive cardiology has the most room to intervene before disease becomes established.

What comes next is likely to be a decade of refinement. Researchers are now designing studies to identify which patients respond best to incretin-based therapies, to determine how inflammatory marker changes translate into hard clinical outcomes, and to establish how long treatment must continue to sustain both weight loss and the anti-inflammatory state it appears to accompany. For the millions of adults living with obesity who do not have diabetes, the accumulating evidence offers a shift in how these drugs are understood: not simply appetite suppressants, but agents that appear to reach into the inflammatory biology that makes excess weight dangerous in the first place. As pooled analyses like this one accumulate, they will help clinicians and patients weigh semaglutide’s benefits with sharper precision—and they underscore how much modern obesity medicine has evolved from a focus on willpower to a rigorous science of hormones, receptors, and immune signaling.

Subject of Research: Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes

Article Title: Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis

Article References: Milluzzo, A., Oteri, V., Manuella, L., Pulvirenti, A., & Frittitta, L. (2026). Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02189-x

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02189-x

Keywords: semaglutide, obesity, weight loss, inflammatory markers, GLP-1 receptor agonist, systematic review, meta-analysis, C-reactive protein, International Journal of Obesity, overweight, non-diabetic adults, cardiometabolic health